Vince Bertucci, MD, FRCPC: Bertucci MedSpa
8333 Weston Road, Suite 100
Woodbridge, ON L4L 8E2
Phone: (905) 850-4415
Hours: Monday: 8 a.m.–5 p.m.
Tuesday: 9 a.m.–5 p.m.
Wednesday – Thursday: 8 a.m.–5 p.m.
Friday: 8 a.m.–4 p.m.

  1. A Phase 2b, Randomized, Placebo-Controlled Factorial Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection Compared with CBL-A1 and CBL-A2 for Reducing Abdominal Subcutaneous Fat (Concluded: 2024)
  2. A randomized, evaluator-blinded, parallel group, no treatment controlled, multicenter study to evaluate effectiveness and safety of Restylane Lyft Lidocaine for jawline definition (Concluded: 2024)
  3. A randomized, evaluator-blinded, parallel group, comparator-controlled, multicenter study to evaluate the safety and effectiveness of GP0112 for cheek augmentation and correction of midface contour deficiencies (Concluded: 2024)
  4. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence (Concluded: 2023)
  5. A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse Shape+ with Lidocaine versus Juvederm Voluma with Lidocaine for the Correction of Age-Related Midface Volume Deficit/Lipoatrophy at 6 and 12 Months Post-treatment (Concluded: 2023)
  6. A randomized, evaluator-blinded, parallel group, no treatment controlled, multicentre study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region  (Concluded: 2022)
  7. A Prospective, Single blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA® Collection of Fillers (Concluded: 2021)
  8. Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane (CHEEKY Study) (Concluded: 2021)
  9. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines (Concluded: 2021)
  10. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (READY – 3) (Concluded: 2021)
  11. A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence (Concluded: 2020)
  12. Canada Global HARMONY: Prospective, Multi-site, Study to Evaluate Subject Satisfaction with Facial Appearance Overall and the Aesthetic and Psychosocial Impact of Combined Facial Treatment (Concluded: 2020)
  13. A Phase 2a, Multicenter, Open-Label, Dose-EscalationStudy to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections (Concluded: 2020)
  14. Post Marketing study to evaluate lip enhancement, naturalness and partner/subject satisfaction after treatment with Restylane Kysse (Concluded: 2019)

Back to Top
Contact